JANUX THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.37 USD | +5.46% |
|
-5.46% | +322.83% |
| May. 08 | Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating | MT |
| May. 08 | Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
| Sales 2024 * | 3.14M | Sales 2025 * | 2.04M | Capitalization | 2.35B |
|---|---|---|---|---|---|
| Net income 2024 * | -74M | Net income 2025 * | -97M | EV / Sales 2024 * | 749 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1,154 x |
| P/E ratio 2024 * |
-33.1
x | P/E ratio 2025 * |
-26.8
x | Employees | 68 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.49% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +5.46% | ||
| 1 week | -5.46% | ||
| Current month | -20.40% | ||
| 1 month | -4.26% | ||
| 3 months | -8.80% | ||
| 6 months | +351.89% | ||
| Current year | +322.83% |
1 week
42.70
46.30
1 month
42.7065.60
Current year
7.7965.60
1 year
5.6565.60
3 years
5.6565.60
5 years
5.6565.60
10 years
5.6565.60
| Managers | Title | Age | Since |
|---|---|---|---|
David Campbell
CEO | Chief Executive Officer | 65 | 17-05-31 |
Tighe Reardon
DFI | Director of Finance/CFO | 48 | 17-05-31 |
Jenna Daly
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vickie Capps
BRD | Director/Board Member | 62 | 21-03-17 |
Jay Lichter
CHM | Chairman | 62 | 17-05-31 |
Ronald Barrett
BRD | Director/Board Member | 68 | 21-09-06 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +10.11% | - | |
| 0.00% | 9 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 45.37 | +5.46% | 695,464 |
| 24-05-23 | 43.02 | -5.14% | 614,935 |
| 24-05-22 | 45.35 | -0.31% | 375,834 |
| 24-05-21 | 45.49 | -5.21% | 879,116 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotes
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Calendar
2024-06-26
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
45.37
USD
Average target price
63.57
USD
Spread / Average Target
+40.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +322.83% | 2.35B | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +43.91% | 40.47B | |
| -10.87% | 27.17B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- JANX Stock
